BACKGROUND: Biomarkers that can be used to accurately assess the residual risk of disease recurrence in @entity1 with hormone receptor-positive @entity0 are clinically valuable. We evaluated the prognostic value of the @entity0 Index (BCI), a continuous risk index based on a combination of @entity29386 : @entity15638 and molecular grade index, in @entity1 with early @entity0 treated with either @entity440 alone or @entity440 plus @entity2390 in the NCIC MA.14 phase III clinical trial (ClinicalTrials.gov Identifier NCT00002864; registered 1 November 1999). METHODS: Gene expression analysis of BCI by real-time polymerase chain reaction was performed blinded to outcome on RNA extracted from archived formalin-fixed, paraffin-embedded @entity5 samples of 299 @entity1 with both lymph node-negative (LN-) and lymph node-positive (LN+) disease enrolled in the MA.14 trial. Our primary objective was to determine the prognostic performance of BCI based on @entity4557 ( @entity4557 ). MA.14 @entity1 experienced similar @entity4557 on both treatment arms. Association of gene expression data with @entity4557 was evaluated in univariate analysis with a stratified log-rank test statistic, depicted with a Kaplan-Meier plot and an adjusted Cox survivor plot. In the multivariate assessment, we used stratified Cox regression. The prognostic performance of an emerging, optimized linear BCI model was also assessed in a post hoc analysis. RESULTS: Of 299 samples, 292 were assessed successfully for BCI for 146 @entity1 accrued in each MA.14 treatment arm. BCI risk groups had a significant univariate association with @entity4557 (stratified log-rank p   =   0.005, unstratified log-rank p   =   0.007). Adjusted 10-year @entity4557 in BCI low-, intermediate-, and high-risk groups was 87.5  %, 83.9  %, and 74.7  %, respectively. BCI had a significant prognostic effect [hazard ratio (HR) 2.34, 95  % confidence interval (CI) 1.33-4.11; p   =   0.004], although not a predictive effect, on @entity4557 in stratified multivariate analysis, adjusted for pathological @entity5 stage (HR 2.22, 95  % CI 1.22-4.07; p   =   0.01). In the post hoc multivariate analysis, higher linear BCI was associated with shorter @entity4557 (p   =   0.002). CONCLUSIONS: BCI had a strong prognostic effect on @entity4557 in @entity1 with @entity0 treated with @entity440 alone or with @entity440 and @entity2390 . BCI was prognostic in both LN- and LN+ @entity1 . This retrospective study is an independent validation of the prognostic performance of BCI in a prospective trial.

Assessment of the prognostic and predictive utility of the XXXX Index (BCI): an NCIC CTG MA.14 study.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity29386 :: ('10481', 'Gene') :: ['HOXB13'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen'] @entity0 :: ('MESH:D001943', 'Disease') :: ['Breast Cancer', 'breast cancer', 'early-stage breast cancer'] @entity4557 :: ('MESH:D012008', 'Disease') :: ['RFS', 'relapse-free survival'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity15638 :: ('55540', 'Gene') :: ['IL17BR'] @entity2390 :: ('MESH:D015282', 'Chemical') :: ['octreotide']
@entity0 :: (MESH:D001943,Disease) :: ['Breast Cancer']
